Advertisement
Dr. Paterson's leadership accomplishments were examined for evidence ofoutstanding management practices that led to significant improvement in thecompany's performance, vision and steps taken to move toward fulfillment ofthat vision, fostering pioneering work with new or important applications inbioscience, and fundraising achievements. The award was presented today at abreakfast reception hosted by the Greater Baltimore Committee, the region'smost prominent organization of business and civic leaders, to recognizeoutstanding achievements in the region's bioscience industry.
Advertisement
"It is a great honor to receive this award, and it is gratifying to behonored within the Baltimore bioscience and business community," stated Dr.Paterson. "Our goal at Alba has been to work with the 3 P's which includeplace, people, and perseverance. We are proud to be in the place ofBaltimore, our people are working hard to create a new medicine for the unmetmedical needs of patients with celiac disease and other inflammatoryconditions, and our perseverance and determination toward achieving this goalis what drives us each day. This award recognizes the progress that Alba hasmade in the past year, and this provides further encouragement in our effortsto address the needs of patients and physicians, to provide value to ourinvestors, and to increase the profile of the Baltimore bioscience communitywithin the region and nationally."
Dr. Paterson has directed the growth of Alba Therapeutics since itsinception in 2004, and his leadership has been characterized by methodical andrapid growth. Alba has grown into a thriving Baltimore biotechnology companywith 45 employees in its headquarters at the University of Maryland BioPark,and this growth has been punctuated by a series of significant milestonesincluding securing significant venture financing, rapid progress of Alba'sclinical candidate (larazotide acetate) into Phase 2b clinical trials, andclosure of a licensing and collaboration agreement worth up to $325 millionwith Shire Pharmaceuticals.
About Alba
Alba Therapeutics Corporation is a privately held, clinical-stagebiopharmaceutical company focused on the discovery, development, andcommercialization of therapies to treat autoimmune and inflammatory diseasesand is based in Baltimore, Maryland. Alba's technology platform is based upona key pathway that regulates the assembly and disassembly of tight junctionsin cell barriers throughout the body. As a result of its unique technologyplatform, Alba is a leader in mucosal biology and has developed a pipeline ofinnovative therapeutic candidates that has the potential to modify the courseof disease and significantly improve upon existing treatments for a wide rangeof diseases such as celiac disease, Crohn's disease, and Asthma/COPD or acutelung injury.Contact: Bernard McDonald, PhD Phone: 410-319-0780 E-mail: [email protected] Web site: http://www.albatherapeutics.com
SOURCE Alba Therapeutics Corporation
